Offer - Urjas Oil for just ₹ 1 X
Gliclapack MV 0.3 Mg/500 Mg/80 Mg Tablet is a commercial drug that is prescribed in the form of Tablet. Gliclapack MV 0.3 Mg/500 Mg/80 Mg Tablet also has some secondary and off-label uses. These are listed below.
The right dosage of Gliclapack MV 0.3 Mg/500 Mg/80 Mg Tablet depends on the age, gender, and medical history of the patient. Besides the medical condition it is advised for, the route of administration also plays an important role in determining the correct drug dosage. For detailed information on this, read through the dosage section.
Gliclapack MV 0.3 Mg/500 Mg/80 Mg Tablet also has some side effects, the most common being Rash, Flatulence, Diarrhoea. Apart from the aforementioned side effects, Gliclapack MV 0.3 Mg/500 Mg/80 Mg Tablet can also lead to other problems, which have been listed below. These side effects of Gliclapack MV 0.3 Mg/500 Mg/80 Mg Tablet are usually temporary and subside with the completion of treatment. Please speak with your doctor if these side effects worsen or persist for a longer duration.
Gliclapack MV 0.3 Mg/500 Mg/80 Mg Tablet's effect during pregnancy is Severe and Severe while nursing. Further, the section on Gliclapack MV 0.3 Mg/500 Mg/80 Mg Tablet related warnings talks about Gliclapack MV 0.3 Mg/500 Mg/80 Mg Tablet's effects on the liver, heart and kidney.
Gliclapack MV 0.3 Mg/500 Mg/80 Mg Tablet can cause adverse effects in certain medical conditions. It is strongly recommended to avoid Gliclapack MV 0.3 Mg/500 Mg/80 Mg Tablet in conditions like Digestive Disorders, Intestinal Obstruction, Allergy. The section on Gliclapack MV 0.3 Mg/500 Mg/80 Mg Tablet contraindications lists all such conditions.
Drug reaction of Gliclapack MV 0.3 Mg/500 Mg/80 Mg Tablet with other medicines has been reported. Refer to the list below for further details.
You should also be aware that Gliclapack MV 0.3 Mg/500 Mg/80 Mg Tablet is safe while driving, and is addiction.
Gliclapack MV 0.3 Mg/500 Mg/80 Mg Tablet is used to treat the following -
Other Benefits
This is the usual dosage recommended in most common treatment cases. Please remember that every patient and their case is different, so the dosage can be different based on the disease, route of administration, patient's age and medical history.
Find the right dosage based on disease and age
Age Group | Dosage |
Adult |
|
Geriatric |
|
Is the use of Gliclapack MV 0.3 Mg/500 Mg/80 Mg Tablet safe for pregnant women?
Gliclapack MV can cause severe side effects if taken during pregnancy, so, pregnant women should talk to their doctor before taking it.
Is the use of Gliclapack MV 0.3 Mg/500 Mg/80 Mg Tablet safe during breastfeeding?
Gliclapack MV should not be taken without taking your doctor's advice, as it may have severe side effects on breastfeeding women.
What is the effect of Gliclapack MV 0.3 Mg/500 Mg/80 Mg Tablet on the Kidneys?
Gliclapack MV may cause harmful effects on kidney. if you feel its having any such effect, then stop taking this drug, and restart only on your doctor's advice.
What is the effect of Gliclapack MV 0.3 Mg/500 Mg/80 Mg Tablet on the Liver?
Gliclapack MV may cause harmful effects on liver. if you feel it's having any such effect, then stop taking this drug, and restart only on your doctor's advice.
What is the effect of Gliclapack MV 0.3 Mg/500 Mg/80 Mg Tablet on the Heart?
Gliclapack MV has very mild side effects on the heart.
If you are suffering from any of the following diseases, you should not take Gliclapack MV 0.3 Mg/500 Mg/80 Mg Tablet unless your doctor advises you to do so -
Is this Gliclapack MV 0.3 Mg/500 Mg/80 Mg Tablet habit forming or addictive?
No, there is no any evidence that Gliclapack MV 0.3 Mg/500 Mg/80 Mg Tablet is addictive.
Interaction between Food and Gliclapack MV 0.3 Mg/500 Mg/80 Mg Tablet
Due to a lack of research, nothing can be said about the consequences of taking Gliclapack MV 0.3 Mg/500 Mg/80 Mg Tablet together with food.
Interaction between Alcohol and Gliclapack MV 0.3 Mg/500 Mg/80 Mg Tablet
Taking alcohol with Gliclapack MV 0.3 Mg/500 Mg/80 Mg Tablet can be dangerous.
Gliclapack MV should be taken as long as needed or take it as directed by doctor. Do not discontinue the drug suddenly or take it longer than prescribed by your doctor.
Yes, Gliclapack MV is safe to use, if taken in prescribed amount and duration as advised by the doctor. However, certain side effects have been associated with this drug such as dizziness, nausea, and vomiting. If you experience any discomfort after taking this medicine then inform your doctor immediately and follow his/her instructions.
Yes, Gliclapack MV can cause some sleep problems. The exact cause of sleep problems is still not clear. It is best to consult your doctor if you experience sleepiness after consuming medicine.
Gliclapack MV contain voglibose. It works by inhibiting the enzyme (alpha-glucosidase) that reduces the rate of digestion of complex carbohydrates. Less glucose is absorbed because the carbohydrates are not broken down into glucose molecules. Hence in this way, Gliclapack MV reduces blood sugar levels.
Gliclapack MV is the brand name for voglibose. It is an oral antidiabetic drug that belongs to the class of medicine called alpha-glucosidase inhibitor. It is used in single or combined with other drugs to treat diabetes.
This medicine data has been created by -
B.Pharma, Pharmacy
5 Years of Experience
References
KD Tripathi. [link]. Seventh Edition. New Delhi, India: Jaypee Brothers Medical Publishers; 2013: Page No 277
US Food and Drug Administration (FDA) [Internet]. Maryland. USA; Package leaflet information for the user; Glucophage® (metformin hydrochloride)
KD Tripathi. [link]. Seventh Edition. New Delhi, India: Jaypee Brothers Medical Publishers; 2013: Page No 275-276
April Hazard Vallerand, Cynthia A. Sanoski. [link]. Sixteenth Edition. Philadelphia, China: F. A. Davis Company; 2019: Page No 825-826
KD Tripathi. [link]. Seventh Edition. New Delhi, India: Jaypee Brothers Medical Publishers; 2013: Page No 272
April Hazard Vallerand, Cynthia A. Sanoski. [link]. Sixteenth Edition. Philadelphia, China: F. A. Davis Company; 2019: Page No 1314-1315